Semagacestat: Development discontinued

Eli Lilly stopped development of semagacestat after preliminary data from the ongoing, double-blind, international Phase III IDENTITY and IDENTITY-2 trials in >2,600 patients showed that oral semagacestat worsened clinical measures of cognition and the ability to perform activities of daily living as measured by the ADAS-Cog11 and ADCS-ADL scales, the co-primary endpoints, by a significantly greater degree compared to placebo. Additionally, semagacestat was associated with an increased risk of skin cancer vs. placebo. Although dosing with semagacestat is being stopped, Lilly said it will continue to collect safety data, including cognitive scores, for at least 6 months. ...